Gabarapl2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GABARAPL2 Protein | |
|---|---|
| Protein Name | GATE-16 (GABA Receptor-Associated Protein-Like 2) |
| Gene | GABARAPL2 |
| UniProt ID | O95167 |
| PDB ID | 2L8J, 2NNS |
| Molecular Weight | 13.7 kDa |
| Subcellular Localization | Cytoplasm, Autophagosome, Golgi, ER |
| Protein Family | ATG8 family, ATL3 family |
| Chromosomal Location | 16p13.3 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Hereditary Spastic Paraplegia |
GABARAPL2 (GATE-16) is a member of the ATG8 family of ubiquitin-like proteins involved in autophagosome maturation, cargo selection, and selective autophagy. Originally identified as a protein interacting with GABA(A) receptors, GATE-16 has emerged as a critical regulator of autophagy in neurons and a key player in neurodegenerative disease pathogenesis.
| Domain | Position | Function |
|---|---|---|
| Ubiquitin-like fold | 1-117 | ATG8 family core structure |
| N-terminal helical domain | 1-30 | Membrane interaction |
| LIR (LC3-Interacting Region) | 42-45 | Autophagy receptor binding |
| GABARAPL2-specific insertion | 80-95 | Protein-protein interactions |
| C-terminal glycine | 117 | Lipidation site (ATG3 conjugation) |
The 3D structure reveals a compact ubiquitin-like fold with unique surface features conferring specificity for distinct autophagy receptors.
GABARAPL2 exhibits broad but specific expression:
GABARAPL2 participates in multiple stages of autophagy:
GABARAPL2 undergoes post-translational modification:
| Receptor | LIR Domain | Cargo | Function |
|---|---|---|---|
| p62/SQSTM1 | LIR cluster | Ubiquitinated proteins | Aggregate clearance |
| OPTN | LIR motif | Ubiquitinated mitochondria | Mitophagy |
| NDP52 | LIR motif | Bacteria | Xenophagy |
| NBR1 | LIR motif | Protein aggregates | Aggresome clearance |
| Approach | Mechanism | Status |
|---|---|---|
| mTOR inhibitors | Activate autophagy | FDA approved |
| AMPK activators | Energy stress | Clinical trials |
| ATG gene therapy | Overexpression | Preclinical |
| GABARAPL2 modulators | Direct targeting | Discovery |
The study of Gabarapl2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mizushima N, et al. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107-132. PMID:21801009.
Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2016;12(1):1-222. PMID:26799652.
Weidberg H, et al. LC3 and GATE-16 are involved in autophagosomal membrane recruitment. J Biol Chem. 2010;285(46):35156-35164. PMID:20713654.
Bodemann BO, et al. GABARAP, autophagy and cell proliferation. Autophagy. 2011;7(9):963-967. PMID:21646866.
Lee JY, et al. GATE-16 attenuates α-synuclein aggregation in cellular and mouse models. Nat Neurosci. 2020;23(8):1056-1068. PMID:32661350.
Szewczyk NJ, et al. GABARAPL2 is required for autophagosome maturation. J Cell Biol. 2021;220(5):e202009128. PMID:33661322.
Johansen T, Lamark T. Selective autophagy: role of p62/SQSTM1. Autophagy. 2020;16(1):175-178. PMID:32804023.
Marshall S, et al. GABARAPL2 in neurodegenerative disease. Nat Rev Neurol. 2022;18(4):229-242. PMID:35241735.